Natera, Inc.

Filed a patent for "methods and compositions for amplifying methylated target dna molecules" on Wed, January 4, 2023

Filed a patent for "method for identifying kidney allograft rejection genes in urine and utility of making those measurements" on Tue, February 7, 2023

Filed a patent for "compositions and methods for identification of chromosomal microdeletions" on Wed, June 29, 2022

Filed a patent for "systems and methods for developing machine learning models for predicting development of preeclampsia" on Tue, August 23, 2022

Filed a patent for "methods for determination and monitoring of transplant rejection by measuring rna" on Wed, September 7, 2022

Filed a patent for "nucleic acid analysis of perfusion or flush fluids" on Thu, October 6, 2022

Filed a patent for "non-invasive methods of assessing transplant rejection in pregnant transplant recipients" on Thu, October 6, 2022

Filed a patent for "methods for determination and monitoring of xenotransplant rejection by measuring nucleic acids or proteins derived from the xenotransplant" on Thu, October 6, 2022

Filed a patent for "donor-derived cell free dna (dd-cfdna) in pregnant kidney transplant recipients" on Fri, January 20, 2023

Filed a patent for "donor-derived cell free dna (dd-cfdna) in pregnant kidney transplant recipients" on Fri, August 4, 2023